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Introduction: There is currently no accurate method of measuring glomerular filtration rate (GFR) during acute
kidney injury (AKI). Knowledge of how much GFR varies in stable subjects is necessary before changes in GFR can
be attributed to AKI. We have designed a method of continuous measurement of GFR intended as a research tool
to time effects of AKI. The aims of this crossover trial were to establish accuracy and precision of a continuous
infusion of low dose Iohexol (CILDI) and variation in GFR in stable volunteers over a range of estimated GFR
(23-138 mL/min/1.73 m2).
Methods: We randomised 17 volunteers to GFR measurement by plasma clearance (PC) and renal clearance (RC) of
either a single bolus of Iohexol (SBI; routine method), or of a continuous infusion of low dose Iohexol (CILDI;
experimental method) at 0.5 mL/h for 12 h. GFR was measured by the alternative method after a washout period
(4–28 days). Iohexol concentration was measured by high performance liquid chromatography/electrospray tandem
mass spectrometry and time to steady state concentration (Css) determined.
Results: Mean PC was 76.7 ± 28.5 mL/min/1.73 m2 (SBI), and 78.9 ± 28.6 mL/min/1.73 m2 (CILDI), p = 0.82. No crossover
effects occurred (p = 0.85). Correlation (r) between the methods was 0.98 (p < 0.0001). Bias was 2.2 mL/min/1.73 m2
(limits of agreement −8.2 to 12.6 mL/min/1.73 m2) for CILDI. PC overestimated RC by 7.1 ± 7.3 mL/min/1.73 m2.
Mean intra-individual variation in GFR (CILDI) was 10.3% (p < 0.003). Mean ± SD Css was 172 ± 185 min.
Conclusion: We hypothesise that changes in GFR >10.3% depict evolving AKI. If this were applicable to AKI, this is less
than the 50% change in serum creatinine currently required to define AKI. CILDI is now ready for testing in patients
with AKI.
Trial registration: This trial was registered with the European Union Clinical Trials Register
(https://www.clinicaltrialsregister.eu/), registration number: 2010-019933-89.
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The absence of an accurate method of measuring chan-
ging glomerular filtration rate (GFR) in acute kidney in-
jury (AKI) poses a significant barrier to research in this
area. Identifying when pathophysiological changes asso-
ciated with AKI occur remains a significant challenge.* Correspondence: bphilips@sgul.ac.uk
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unless otherwise stated.Current definitions of AKI are based upon an increase
in serum creatinine concentration (SCr) of greater than
50% or reduction in urine output (UO) [1-3] despite lim-
itations in interpretation of these parameters in critically
ill patients [4]. Changes in SCr sufficient to define AKI
may be delayed, particularly in patients with chronic kid-
ney disease (CKD) [5] or sepsis [6]. Acute illness may
lead to diminished creatinine formation [7] limiting its
utility as a biomarker for GFR in AKI. Other endogen-
ous biomarkers have been investigated but have variable
performance [8]. None have been proven to be superiorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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critical care units), or where the onset of the insult or its
aetiology is unclear.
Using exogenous markers, such as radioactive ethylene
diamine tetraacetic acid (EDTA) or radio-opaque contrast
media, to measure GFR in AKI have advantages over en-
dogenous markers: they are not influenced by body habitus,
diet or metabolic processes, and are not dependent on the
timing of the insult causing AKI. Exogenous markers can
theoretically be administered as a single bolus injection and
measuring the time to elimination from the body, or as a
continuous infusion. Single bolus injection of Iohexol (SBI)
has been used in critically ill patients [9], but interpretation
of this approach assumes stable GFR, which is unlikely in
the context of evolving AKI: administration would need to
be repeated frequently to track changing GFR, and may
lead to accumulation of Iohexol. Furthermore, bolus
methods are inappropriate in AKI because of the washout
period required.
Continuous infusions require stable GFR and volume of
distribution (Vd) to achieve steady state concentration
(Css). They are limited by natural intra-individual varia-
tions in GFR (precision) and bias of laboratory analytical
equipment. Css varies between patients according to: a)
baseline GFR, b) Vd, and c) the mass of substance infused
over time (Minf). In stable patients (a) and (b) are un-
changed, and (c) is controlled by the operator. Css can be
predicted if the subject’s weight and baseline GFR are
known. Once Css has been reached, variations in GFR oc-
curring after this time, in excess of precision and bias,
likely represent true changes in GFR. Theoretically, mea-
surements made after time to Css will represent GFR at
that moment. A loading dose (LD) given prior to the infu-
sion reduces time to Css: if LD is too large, plasma con-
centration declines until Css is reached; if too small,
plasma concentrations climb until Css is reached. In AKI,
Cssmay never be reached, however, plasma measurements
made after the predicted time to Css can detect changes
from baseline GFR and predicted Css. In rapidly evolving
AKI occurring before time to Css, concentrations will not
change towards Css at the expected rate, and may even in-
crease. To date, there have been no studies measuring
changing GFR in AKI using continuous infusions.
Administration of a continuous infusion of low dose
Iohexol (CILDI; Omnipaque 300®, at 0.5 mL/h) has the
potential to measure evolving GFR in AKI. A continuous
infusion of Iohexol has previously been validated in sub-
jects with normal GFR [10], however, Css and time to
Css in subjects with CKD are unknown: prolonged time
to Css in patients with CKD would limit the applicability
of CILDI in patients with AKI.
We have performed a proof-of-method clinical trial
(randomised crossover design) with the aim of validating
CILDI for measuring GFR as a research tool in AKI.CILDI was compared to measurement of the plasma
clearance (PC) of a SBI [9,11]. We have used the SBI
method as our “gold standard”, rather than a continuous
infusion for three reasons: 1) The SBI method has previ-
ously been validated to measure a wide range of GFR in
stable patients, from normal to measuring residual renal
function in patients requiring renal replacement therapy
[11,12]. We are therefore confident that the SBI method
is accurate and precise. 2) The SBI method previously
used in critically ill patients [9] may be regarded by
some authors as a “gold standard”, however, we think
this is inappropriate in AKI for reasons listed above. We
wanted to demonstrate that CILDI is not inferior to the
SBI method when measuring GFR in stable patients; 3)
No continuous infusion has been tested in AKI and after
proof of methods our intention is to test the method in
such patients. Urine was collected, so that Iohexol renal
clearance (RC) could be measured. Healthy volunteers
(HV; defined as estimated GFR >60 mL/min/1.73 m2 by
the simplified MDRD equation [13]) and patients with
stable CKD (defined as eGFR <60 mL/min/1.73 m2)
were recruited so that the variability of GFR in stable pa-
tients using our method could be determined over a
wide range of GFR equivalent to that expected to occur
in patients developing AKI. The range of eGFR in the
HV cohort was 75-138 mL/min/1.73 m2, and the eGFR
range in the CKD cohort was 23-59 mL/min/1.73 m2.Objectives
1) Compare the performance of CILDI with the SBI
method in HV and patients with stable CKD. 2) Meas-
ure intra-individual variation of GFR in stable subjects,
so that the minimum change in GFR (precision) de-
tected by CILDI can be determined. 3) Confirm that
subjects with eGFR >23 mL/min/1.73 m2 have time to
Css <12 hours.
This article represents the first stage: validation of the
technique and establishment of the accuracy and preci-
sion in subjects with stable GFR. The goal is to use
CILDI in patients with, and at risk of, developing AKI.
Changing GFR associated with AKI can be measured by
PC and RC at various time points after predicted time to
Css, allowing the temporal relationship between AKI
and its pathophysiological effects to be delineated.Methods
Clinical trial registration and ethics
This trial was registered with the European Union Clinical
Trials Register (https://www.clinicaltrialsregister.eu), regis-
tration number: 2010-019933-89. Approval was obtained
from Brighton East Research Ethics Committee (Ref: 10/
H1107/24). The Declaration of Helsinki (2008) [14] was
adhered to throughout. All subjects provided prior written
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University of London, United Kingdom.
Setting
The trial took place in the Clinical Research Facility, St.
George’s, University of London. Research methods were
performed to International Conference for Harmonisation
Good Clinical Practice standards [15].
Recruitment, inclusions and exclusions
Subjects were recruited from local Nephrology out-
patient clinics or via advertisements placed on public
notice boards within St. George’s Healthcare NHS Trust
or St. George’s, University of London.
Inclusions
Adults aged 18–75 years with renal function ranging
from normal to chronic kidney disease (CKD) stage 4.
Subjects were classified as having CKD if their estimated
GFR was <60 mL/min/1.73 m2 by the simplified MDRD
equation [15] or healthy volunteers (HV) if eGFR was
>60 mL/min/1.73 m2.
Exclusions
These were precautionary and based on the listed cri-
teria for radio-opaque contrast media [16]. Reactions
to radio-contrast media; thyroid disease, myasthenia
gravis, cardiac arrhythmias, pulmonary hypertension,
epilepsy, structural brain disease, phaeochromocytoma,
advanced heart failure, sickle cell disease, multiple mye-
loma, homocystinuria, ascites, pregnancy or breast-
feeding, renal replacement therapy; subjects taking
Metformin if serum creatinine >150 μmol/L, Phenothi-
azines, Tricyclic antidepressants, Monoamine oxidase
inhibitors, Levo-thyroxine, Amiodarone, Interleukin-2
agents; a planned Tc99m–labelled scan. Subjects unable
to provide written Informed Consent were also excluded.
Study design and randomisation
Computer-generated block randomisation allocated subjects
to measurement of GFR via Method A (plasma clearance of
a single bolus of Iohexol; SBI), or Method B (continuous in-
fusion of low dose Iohexol; CILDI). Subjects then under-
went a washout period of 4–28 days before GFR was
measured by the alternative method. Four days was chosen
as the minimum washout period because we wanted to en-
sure that subjects entering the second part of the crossover
study had no remaining Iohexol within their body, and
4 days is more than double the time for Iohexol to be com-
pletely eliminated in a subject with GFR <20 mL/min/
1.73 m2 [11,16]. An epidemiological study has suggested the
rate of progression of CKD in stable subjects may be as high
as a loss in GFR of 3.1 mL/min/1.73 m2 per year [17], so
28 days was chosen as the maximum washout period tominimise the likely risk of GFR changing between the two
methods. A crossover design was used to further mitigate
potential bias caused by changing clinical conditions.
Iohexol administration and sampling
Procedures common to both methods: body surface area
(BSA) was calculated from height and weight [18]. An
intravenous cannula was inserted into each arm. Iohexol
was administered via one cannula and 2 mL blood sam-
ples collected from the other into serum separator con-
tainers. Serum was centrifuged at 4°C at 3500 rpm for
10 min. Every time urine was voided, subjects’ bladders
were scanned to ensure complete emptying (Bladders-
can® BVI9400, Verathon Medical UK Ltd.). Urine and
serum samples were stored at −80°C. The CKD group
received intravenous 1.4% Sodium Bicarbonate 100 mL/h,
in accordance with local hospital guidelines. Healthy
volunteers were encouraged to drink 100 mL/h water.
Volunteers were allowed to eat and drink freely.
Method A (SBI)
5 mL Iohexol (Ominpaque 300®) was administered as an
intravenous bolus over 2 minutes [9]. The first blood sam-
ple was collected at 5 minutes. This allowed later confirm-
ation that intravenous administration had occurred (a
high concentration at 5 min suggests intravenous, rather
than subcutaneous, injection). Samples were collected at
2 h, 3 h, and 4 h to calculate GFR. Urine was taken to
measure renal clearance twice.
Method B (CILDI)
An intravenous loading dose (LD) was administered ac-
cording to the formula:
LD ¼ volume of distribution Vdð Þ
 target steady state concentration Cssð Þ
From the Summary of Product Characteristics [16],
Vd = 0.165 L/Kg (95% CI: 0.108-0.219) ×Weight (Kg).
The target steady state concentration (100 μmol/L) is
approximately 100 times the lower limit of quantitation
by high performance liquid chromatography/tandem
mass spectrometry (LC-MSMS): the actual steady state
achieved in individuals was likely to vary according to
their GFR and Vd. Ideally the LD would be calculated
using GFR, however, weight was used so that CILDI
could eventually be used in patients with an unknown
baseline GFR. A continuous intravenous infusion of
Iohexol (Omnipaque 300®) was then administered at
0.5 mL/h (343.5 mg/mL) for 12 h (Agilia MC Injectomat,
Fresenius Kabihas) [19]. Blood samples were taken at
30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, and
12 h. Urine samples were collected between each plasma
sample, when possible.
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Method A: the natural logarithms of serum Iohexol con-
centrations at 2 h, 3 h, and 4 h were plotted against time.
The intercept and slope were used to derive the theoretical
time zero concentration of Iohexol, Vd and plasma half-
life (T1/2). GFR was calculated by dividing the product
Loge(2)*Vd by T1/2, adjusting for BSA [18] and applying
the Bröchner-Mortensen single compartment correction
factor [20]. Renal Clearance (RC) was derived by measur-
ing the urine concentration at 2.5 and 3.5 h and calculat-
ing the corresponding plasma concentration at 2.5 h and
3.5 h from the log-concentration-time graph, and using
the formula: GFR(mL/min) = [U ×V]/P. Where U = urine
Iohexol concentration (μmol/L),V = volume of urine (mL)
per unit time (min), and P = plasma Iohexol concentration
(μmol/L), adjusting for BSA [18]. The mean of the two
values was used for RC.
Method B (CILDI): results were plotted on a 2-phase
exponential decay curve, and the plateau concentration
calculated. Plasma clearance was calculated by the formula:
GFR(mL/min) = [Iohexol infusion rate (μmol/min)]/[serum
plateau Iohexol concentration (μmol/mL)], and adjusting
for BSA. Renal clearance was calculated when bladder void-
ance and urine collection were complete, by measuring urine
concentration of Iohexol at the mid-time point between each
plasma sample after the time to steady state had been
reached. The mean value of a minimum of two measure-
ments was used for each subject.
Laboratory procedures
The detailed LC-MSMS method for measurement of
plasma Iohexol and Creatinine has been published [21]. A
brief summary follows: Frozen samples were defrosted at
4°C and centrifuged at 1500 rpm at 4°C for 4 minutes to
separate particulate matter. Serum was decanted into 10 μL
aliquots. 50 μL of stabilising fluid was added to each
aliquot. This consisted of 10 mL de-ionised water, 250 μL
D5-Iohexol, 25 μL D3-Creatinine, 25 μL D6-asymmetrical
dimethylarginine, and 1.5 μL symmetrical dimethylarginine.
200 μL 1% (vol/vol) acetonitrile (Rathburn Chemicals Ltd.,
Walkerbrum, Peebleshire, UK) was added to precipitate the
mixture, before centrifugation at 20000 rpm for 3 minutes
at 4°C. 200 μL of the mixture was transferred into a 96-well
polypropylene well plate and analysed by the API 5000LC/
msms with QJET Ion guide accelerated by LINAC® collision
cell (AB Applied Biosystems MDS SCIEX). Three quality
controls were used with known plasma concentrations of
Iohexol (10.6 μmol/L, 516.0 μmol/L, and 99.2 μmol/L).
Accuracy and precision
Tubular Creatinine secretion varies between 10 and 40%
[22]. The proportion of secreted Creatinine can be mea-
sured by calculating the fractional excretion of creatinine
(ie the fraction of filtered creatinine excreted in theurine divided by measured GFR). Values >100% imply
additional tubular secretion. Accurate intravenous ad-
ministration of Iohexol was confirmed by calculating
the fractional excretion of Creatinine (FeCreat), using
Iohexol as the substitute for GFR. FeCreat >140% implies
that the Iohexol was not administered intravenously.
Inaccurate results were not analysed further. Accuracy
of GFR measurement by CILDI was determined by per-
forming a Bland-Altman comparison [23] against the
SBI method.
GFR calculation during single Iohexol bolus administra-
tion was deemed precise if the Pearson correlation co-
efficient of the loge(Iohexol concentration)-time graph
was < −0.985 [24]. Precision of CILDI was calculated by
measuring co-efficient of variation (CV) and standard de-
viation of Iohexol measurements at steady state; from this,
precision at the 95% and 99% confidence levels and at 3
standard deviations were calculated, allowing mean intra-
individual variation in GFR to be determined.Sample size calculation
A difference in mean GFR of <10% between the two
methods was considered acceptable [11,12]. The intra-
individual CV of repeated measurements of Iohexol
plasma clearance has been reported as 5.4% [25]. Based
on this, a sample size of 30 subjects has 90% power to
detect a GFR difference of 4.7 mL/min/1.73 m2 from
the mean and a sample size of 17 subjects has 82%
power. The sample size was revised to 17 subjects fol-
lowing an interim analysis that demonstrated the differ-
ence between the means of both methods was actually
3.5% and the trial was stopped early because we had
already recruited more than the required number of
subjects. A revised power calculation revealed that a
sample size of 17 subjects has 90% power to detect a
difference between the means of 2.6 mL/min/1.73 m2
whereas 30 subjects would have >99% power.Statistical methods
A futility analysis was performed to determine whether
results would be different if our trial continued until 30
subjects had completed it. Logarithmic transformation
of GFR was performed and data were compared using
the paired 2-tailed t-test, assessing for period effects
during this crossover trial. Difference in mean GFR was
compared using the t-test. Linear regression using
Pearson’s correlation was performed to assess associ-
ation between the methods, and level of agreement was
assessed by the Bland Altman comparison [23]. Graphpad
Prism®, version 5.0d (Graphpad software, Inc.) was used
for statistical analysis. Because the trial was stopped early,
all statistical results were reviewed and approved by a stat-
istician independent to our trial.
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Screening, enrolment and subjects
Twenty-one subjects entered both parts of the crossover
trial. Four subjects were excluded from full analysis: 3 be-
cause of Iohexol administration errors and 1 because of an
emergency evacuation of the building during method B.
Seventeen subjects completed the trial for the measure-
ment of Iohexol PC. RC was accurately measured in 9
subjects. Details are outlined in Figure 1. Demographic de-
tails are summarised in Table 1. Accuracy and precision of
Iohexol GFR measurements are listed in Table 2. Labora-
tory measurements were deemed accurate if the fractionalFigure 1 Subject screening and participation. No adverse effects due to
chronic kidney disease.excretion of Creatinine (FeCreat), using Iohexol as the de-
nominator, was 110-140%; subjects with inaccurate results
were excluded. There was no difference in SCr and cre-
atinine clearance in subjects between the two Iohexol GFR
study periods (Table 3).
Association, agreement and precision of GFR calculations
There was no significant difference in PC between
methods A (SBI) and B (CILDI) overall or on sub-group
analysis; Table 3. Association (Figure 2) and agreement
(Figure 3) between the methods were good. Sub-group
analysis revealed closer limits of agreement, whenIohexol were observed. HV = healthy volunteers; CKD = Patients with
Table 1 Demographic features of trial subjects
Subject Age Sex Ethnicity BSA (m2) eGFR* (mL/min/1.73 m2)
Healthy volunteers
1 27 F AC 1.58 134.9
2 30 F C 1.75 111
3 20 F C 1.90 138
4 23 F C 1.82 98.7
5 28 M C 2.11 114.5
6 46 F C 1.69 74.9
7 51 M C 2.11 87.7
8 35 M A 1.65 108.7
9 55 F C 1.74 99.9
10 71 M C 1.95 100.3
11 49 M A 2.03 81.1
Chronic Kidney Disease
12 49 F AC 1.78 34.1
13 74 M C 2.05 27.2
14 72 M C 2.00 46.3
15 55 M C 1.83 59.0
16 51 F A 1.87 49.4
17 74 M C 2.00 23.0
BSA = body surface area, F = female, M =male, AC = Afro-Caribbean, C = Caucasian,
A = Asian. *eGFR = estimated glomerular filtration rate based upon the simplified
MDRD equation28. Subjects were classified as healthy volunteers if eGFR > 60 mL/
min/1.73 m2 and as CKD if eGFR <60 mL/min/1.73 m2.
Table 2 Accuracy and precision of Iohexol measurements
during methods A (single Iohexol bolus) and B (CILDI)
Subject Method A Method B Method A Method B
(FeCreat; %) (FeCreat; %) Precision
(Pearson’s r)
Precision (CV; %)
[no. samples]
Healthy Volunteers
1 131.7 130.8 −1.00 2.1 [7]
2 132.9 126.0 −1.00 4.4 [4]
3 125.7 122.1 −1.00 1.8 [6]
4 123.7 118.4 −1.00 6.6 [4]
5 117.2 120.4 −0.99 1.8 [7]
6 125.8 122.9 −1.00 2.0 [6]
7 121.8 125.3 −0.99 0.5 [8]
8 133.7 120.3 −0.99 1.6 [5]
9 128.1 128.7 −0.99 3.0 [7]
10 131.5 123.0 −0.97 3.8 [6]
11 121.0 120.4 −0.99 3.2 [6]
Mean 126.6 123.6 2.8 [6]
Chronic Kidney Disease
12 120.7 118.1 −1.00 2.8 [3*]
13 129.8 127.7 −0.99 4.2 [3*]
14 132.8 132.0 −1.00 4.8 [3*]
15 133.4 132.6 −1.00 2.5 [4]
16 133.0 128.4 −1.00 2.2 [3]
17 131.4 133.1 −0.90 2.6 [3*]
Mean 130.2 128.6 3.2 [3]
All volunteers
Mean 127.9 125.5 2.9
Measurements were considered to be accurate if FeCreat of 110-140%, using
Iohexol as the denominator. Precision in method A is measured by the correlation
between the loge Iohexol concentration and time. The measurements are
deemed to be precise if: −0.99 ≤ r ≥ −1. Correlation is rounded to 2 decimal
places. Precision in method B is measured by the co-efficient of variation (CV) of
Iohexol concentration measurements once steady state had been achieved, and
has been rounded to two significant digits. The number of samples used is in
parentheses. In subjects with time to steady state >8 h, the last 3 samples were
used (*). FeCreat= fractional excretion of Creatinine, r = Pearson’s correlation,
HV = healthy volunteers, CKD = chronic kidney disease.
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though this was not significant when measured as percent-
age difference in GFR. When GFR was measured by
CILDI, bias in the HV group was 2.2 mL/min/1.73 m2
(2.2%), limits of agreement −10.7 to 15.1 mL/min/1.73 m2
(−12.1 to 16.6%); in patients with CKD bias was 2.2 mL/
min/1.73 m2 (5.8%), with limits of agreement −1.3 to
5.7 mL/min/1.73 m2 (−5.0 to 16.6%). Intra-individual vari-
ations in GFR and precision of GFR calculations are sum-
marised in Table 4. Time to steady state (Css) was less
than 10 h in all subjects (Table 4). The difference in GFR
which depicts AKI can be determined by measuring the
precision of CILDI at 95% and 99% confidence intervals
and at 3 standard deviations (ie 99.7% confidence inter-
vals). A difference of greater than 10.3% (3 standard devia-
tions) after time to Css had elapsed, depicts a true
difference in GFR (p < 0.003). The Pearson correlation be-
tween time to steady state concentration and GFR is 0.82.
Plasma and renal clearance
Post-micturition bladder scans revealed incomplete bladder
voiding in 8 subjects; making RC difficult to perform accur-
ately. Consequently, only 9 RC were performed satisfactor-
ily. Although the correlation between PC and RC was 0.989
(Figure 4), measurement of GFR by PC overestimated RC
of Iohexol by 7.1 ± 7.3 mL/min/1.73 m2 (Table 2; Figure 5).Assessment for crossover effects
The Kolgomorov-Smirnov test confirmed GFR measure-
ments had Gaussian distributions during both methods,
before and after logarithmic transformation of data. No
period effect was observed using raw data (paired 2-tailed
t-test; p = 0.85) or transformed data (paired 2-tailed t-test;
p = 0.91) [26]. Pairing of raw and transformed data were
matched (Pearson’s r =0.98, p < 0.0001).
Futility analysis
An interim analysis was conducted after the first batch
analysis of samples. The ratio of the means has a differ-
ence of 3.5% (95% CI: 0.998 to 1.071). A futility test was
performed to determine whether mean GFR observed in
Table 3 Comparison of GFR measurements during method A (single Iohexol bolus) and method B (CILDI)
Creatinine Iohexol
Plasma (μmol/L) Clearance (mL/min/1.73 m2) Plasma clearance
(mL/min/1.73 m2)
Renal clearance
(mL/min/1.73 m2)
Subject A B A B A B A B
Healthy Volunteers
1 59.7 65.7 101.9 107.4
2 58.8 62.9 105.4 105.3
3 52.3 61.0 100.7 102.6
4 68.2 68.6 104.2 105.1
5 75.0 75.5 119.3 127.7
6 76.6 78.7 101.9 100.3 89.1 82.0 79.5 75.8
7 85.1 90.1 115.5 104.7 97.5 89.1 105.1 92.3
8 75.5 77.7 70.7 77.3 80.7 92.1
9 55.3 57.9 120.6 112.1 83.2 83.2 78.8 87.0
10 69.6 71.4 98.7 101.0 77.9 89.4
11 94.7 91.6 105.5 104.7 87.7 88.0 95.4 85.1
Mean ± SD 70.1 ± 13.0 72.9 ± 11.3 102.2 ± 17.5 100.0 ± 11.9 95.2 ± 12.6 97.4 ± 13.6 89.7 ± 12.8 85.1 ± 6.9
P value P = 0.59 P = 0.46 P = 0.75 P = 0.54
Chronic Kidney Disease
12 177.0 200.2 43.8 43.9 40.7 40.5 33.7 33.4
13 219.8 215.9 38.6 36.9 33.9 38.5 27.0 23.3
14 139.3 146.8 25.8 22.8 41.3 44.3
15 118.3 126.5 78.6 77.2 61.2 62.2 53.5 50.8
16 100.0 108.0 40.7 46.9 51.7 52.9 38.8 37.6
17 243.5 253.9 26.6 23.8 28.3 31.7 26.0 18.6
Mean ± SD 166.3 ± 57.2 175.2 ± 57.2 42.4 ± 19.3 41.9 ± 20.0 42.8 ± 12. 45.0 ± 10.9 35.8 ± 11.2 32.7 ± 12.6
P value P = 0.79 P = 0.77 P = 0.70 P = 0.70
All volunteers
Mean ± SD 104.0 ± 58.1 109.0 ± 60.3 72.2 ± 35.8 70.9 ± 34.2 76.7 ± 28.5 78.9 ± 28.6 59.8 ± 30.5 56.0 ± 29.3
P value P = 0.81 P = 0.93 P = 0.82 P = 0.79
GFR has been rounded to one decimal place. The student’s t-test was used to calculate P values comparing method A clearances with method B. CI = confidence
interval, SD = standard deviation, HV = healthy volunteer, CKD = chronic kidney disease.
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until 30 subjects had been recruited. The limit of 10% is
5.8 standard errors beyond the observed difference of
3.5% and so a 10% difference is ruled out at p < 10−7.
Discussion
Summary of results
We have demonstrated that measurement of the plasma
clearance of CILDI is accurate and precise. There is an ex-
cellent correlation (Figure 2) with the plasma clearance of a
single Iohexol bolus, and Bland Altman comparison [23]
reveals a small bias with close limits of agreement (Figure 3).
During CILDI, mean intra-individual variation in GFR was
10.3% (p < 0.003). Once the time to steady state concentra-
tion (Css) had elapsed, all subjects reached Css within 10 h.
It is theoretically possible to determine change in GFR fromsingle measurements of Iohexol made after 10 h: variations
greater than 10.3% represent changing GFR. If these data
were applicable in the context of AKI, this is significantly
less than the 50% change in SCr needed to define AKI by
current criteria [1-3]. Intra-individual fluctuations in GFR
may be caused by differences in fluid balance throughout
the day [27] and circadian rhythms [28]. Correlation and
agreement between CILDI plasma and renal clearance,
when measured, were also good (Figures 4 and 5). Figure 6
demonstrates an increased steady state concentration in
CKD subject 15, compared with HV subject 5.
Iohexol has many properties of an “ideal GFR marker”
[29]: it diffuses rapidly into the extracellular space; it
undergoes less than 2% protein binding; over 99% is fil-
tered at the glomerulus [16]; and it undergoes no renal
tubular reabsorption or secretion. It has an excellent
Figure 2 Association between plasma clearance GFR calculated by the single bolus and the experimental continuous infusion of low
dose Iohexol (CILDI). Solid line = line of association, dashed lines = error margins of association line. Slope = 0.988 ± 0.048, Intercept = 3.08 ± 3.92,
Pearson’s correlation, r = 0.983, p < 0.0001.
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ance liquid chromatography / electrospray tandem mass
spectrometry (LC-MSMS), gives highly reproducible re-
sults with low inter- and intra-patient coefficient of vari-
ation [31]. LC-MSMS has been validated to accurately
and precisely measure plasma Iohexol concentrations
less than 10 μmol/L, minimising volumes needed for ad-
ministration [31]. Accuracy of bolus injection of Iohexol
to measure GFR has been confirmed in studies compar-
ing it with Inulin infusions [12], and it is substantially
cheaper and more readily available than Inulin [32].
An infusion of Iohexol over 4 hours has previously
been validated to measure GFR in subjects with normal
renal function [10], however, we have modified this is 2
ways. First, we have employed a much lower dose of
Iohexol. This has allowed us to increase the duration of
the infusion to more than 72 hours, maintaining the
total dose given well within safe limits. Secondly, we
have also tested the method in patients with stable CKD
with a wide range of GFR from normal to <30 mL/min/
1.73 m2. Six of the subjects in our healthy volunteer cat-
egory met criteria for CKD stage 2 [33]; the patient with
the lowest GFR in the CKD group had CKD stage 4. If
the time to Css were markedly increased in patients with
CKD, then this would limit the applicability in patients
with AKI. In our trial, time to Css was under 10 hours.
We hope these modifications will allow us to apply this
method in patients with AKI.CILDI could potentially be continued for prolonged pe-
riods (e.g. up to 6 days), with regular plasma and urine
measurements, allowing the course of moderate and
slowly developing AKI to be monitored. It is also po-
tentially useful in rapidly evolving AKI because Iohexol
concentrations will continue to rise, rather than move to-
wards the expected Css. Although time to Css is <10 h,
subjects with known baseline GFR >60 mL/min/1.73 m2,
will have time to Css155 ± 126 min (Table 4), thus increas-
ing the potential applicability of CILDI to detect rapidly
evolving AKI if Css is not achieved within this time. This
also applies to SCr, however, CILDI has theoretical advan-
tages over SCr because the production rate of creatinine is
often reduced in critically ill patients with AKI [7]. In
addition, LC-MSMS measurements of Iohexol concen-
tration are more accurate than routine laboratory SCr
measurements.
Limitations
Our data are limited to a small number of subjects with
stable GFR and Vd. Although the subjects in our trial
may differ from patients with AKI, this study lays the
groundwork for studies in patients with AKI, providing
an evidence base that CILDI may be preferable to SCr as
a research tool. Patients with AKI are unlikely to reach
equilibrium, however, it will theoretically be possible to
measure changes in GFR occurring after time to Css, or,
in rapidly developing AKI occurring before time to Css,
Figure 3 Bland-Altman comparison of plasma clearance GFR by
single Iohexol bolus method and the experimental method
(CILDI). Central solid lines are bias and outer dashed lines are limits
of agreement, n = 17. A) Difference is measured in mL/min/1.73 m2.
Bias = 2.2 mL/min/1.73 m2, SD of bias = 5.3 mL/min/1.73 m2, 95%
limits of agreement from −8.2 to +12.6 mL/min/1.73 m2, B) Difference
is measured as percentage difference in GFR. Bias = 3.5%, SD of
bias = 6.8%, 95% limits of agreement from −9.8 to +16.8%.
Table 4 Precision of GFR measurements and time to
steady state during CILDI
Method B Precision (Plasma clearance)
Subject 95% CI 99% CI 3 SD^ Time to steady state (min)
[no. samples]
Healthy Volunteers
1 2.9 3.9 4.5 98 [7]
2 10.4 13.6 15.9 248 [4]
3 2.7 3.6 4.2 126 [6]
4 8.3 10.8 12.7 287 [4]
5 1.3 1.7 2.0 118 [7]
6 3.1 4.0 4.7 127 [6]
7 4.5 6.0 6.9 86 [8]
8 3.5 4.7 5.4 205 [5]
9 4.7 6.2 7.2 110 [7]
10 5.8 7.6 8.9 154 [6]
11 1.0 1.4 1.6 143 [6]
Mean ±
SD
4.4 ± 2.9 5.8 ± 3.7 6.7 ± 4.4 155 ± 126
Chronic Kidney Disease
12 6.6 8.7 10.2 555 [3*]
13 17.7 23.2 27.1 598 [3*]
14 15.8 20.8 24.2 508 [3*]
15 6.3 8.3 9.6 327 [4]
16 6.9 9.1 10.6 335 [3]
17 12.5 16.3 19.1 600 [3*]
Mean ±
SD
11.0 ±
5.1
14.4 ±
6.6
16.8 ±
7.4
487 ± 65
All Volunteers
Mean ±
SD
6.7 ± 4.9 8.8 ± 6.4 10.3 ±
7.4
172 ± 185
Precision of individual GFR measurements was calculated for each subject
during CILDI to confidence intervals (CI) of 95% and 99%, and to 3 standard
deviations (SD). Precision results are expressed as percentages. ^3SD = 99.7%
CI. Theoretical time to steady state (Css) was calculated by drawing a 2-phase
exponential decay curve, using Graphpad Prism®, version 5.0d (Graphpad software,
Inc.). All samples used after this time was achieved were used, except where Css
was >8 h. In these circumstances, the last 3 samples were used (*).
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than the expected approach towards Css. The natural
history of AKI and the timing of when its associated
pathophysiological changes occur are unknown. Although
CILDI detects smaller changes in GFR than needed in SCr
to define AKI, it is possible that the pathophysiological ef-
fects may occur at changes too small to detect with CILDI.
Furthermore, they may occur before time to Css. A pre-
sumption in using CILDI is that the baseline eGFR is
known, or at least >23 mL/min/1.73 m2, and hence CILDI
may not be suitable for all patients, or it may not be reli-
able once GFR drops to very low values. In most cases of
AKI, however, we anticipate that fluctuations in Css will
be observed with CILDI.
LC-MSMS allows quantification of relatively low con-
centrations of Iohexol, but is not readily available and
requires time and expertise to obtain results. This
method is, therefore, not currently suitable for routine
clinical use; it is primarily useful as a research tool tomeasure evolving GFR in AKI so that pathophysiological
effects can be measured and timed accurately. It will also
allow monitoring of the natural history of AKI in specific
disease states (e.g. sepsis, post nephrectomy, following
major surgery). Other Iohexol GFR techniques (e.g. blot-
ting) require higher concentrations of Iohexol than
CILDI and pre-dispose towards toxicity. LC-MSMS is
required, however, because of its specificity. It is possible
that other laboratories may have a precision that is dif-
ferent from 10.3% at 3 standard deviations, so this study
needs external validation; the co-efficient of variation in
our Iohexol measurements, is, however, similar to that
in the literature [31].
Figure 4 Correlation between plasma and renal clearance during CILDI. Solid line = line of association, dashed lines = error margins of
association line. Pearson’s correlation (r) = 0.989, Intercept = −23.3 ± 4.8, slope = 1.25 ± 0.07.
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ance by 7.1 ± 7.3 mL/min/1.73 m2 (Figure 5). This is, how-
ever, less than the difference of approximately 10 mL/min/
1.73 m2 observed in studies measuring GFR with Inulin
and EDTA [34,35]. The difference between renal clearance
and plasma clearance was more apparent in subjects with
lower GFR. Our study demonstrates that, even under ex-
perimental conditions, “gold standard” urine collection
and bladder voiding are often incomplete without urinaryFigure 5 Bland-Altman comparison of plasma clearance GFR
and Renal clearance GFR during CILDI. Difference is measured in
mL/min/1.73 m2. Bias = −7.1 mL/min/1.73 m2, SD of bias = 7.3, 95%
Limits of agreement = −21.5 to +7.2 mL/min/1.73 m2. n = 9.
Although based on small numbers sub-group analysis suggests a
smaller bias in the HV group. In the HV group bias was −0.5 mL/min/
1.73 m2 (limits of agreement −10.0 to +8.9 mL/min/1.73 m2); in the
CKD group bias was −12.4 mL/min/1.73 m2 (limits of agreement −19.0
to −5.8 mL/min/1.73 m2).catheterisation. This limits precision of measurements;
GFR measurement with urine collection is therefore not
sufficiently robust for routine clinical application. Three
patients were excluded due to subcutaneous injection
when administered via peripheral cannulae; it may be
more appropriate to administer CILDI via central venous
catheters in clinical settings.
Radio-contrast agents have been associated with AKI
[36], although recent meta-analyses [37,38] show no dif-
ference in the incidence of AKI occurring in patients re-
ceiving contrast and matched controls without contrast.
This implies that AKI occurring after contrast adminis-
tration is likely to be multi-factorial and may be more at-
tributable to the underlying illness than contrast media.
This particular aspect of AKI aetiology is the subject of
on going debate within critical care societies and war-
rants its own detailed investigation before final conclu-
sions can be made. Proponents suggest a threshold ratio
of iodinated contrast volume to weight and baseline
renal function that has to be exceeded before contrast-
associated AKI develops [39]. If CILDI were continued
for 72 h, the volume of Iohexol used is less than half this
ratio for an adult weighing 40Kg and, if all the Iohexol
accumulated, would take a minimum of 6 days before
this threshold was exceeded. Conversely, bolus Iohexol
injection [9] would require repeated administration of
larger volumes of Iohexol to measure changing GFR in
critically ill patients and the threshold for toxicity would
be exceeded much sooner. In addition, the washout
period required makes bolus methods unsuitable for use
in AKI.
Figure 6 Examples of Iohexol concentrations achieved during Method B (CILDI). Different steady state concentrations were observed in
subjects 5 and 15. GFR in subject 5 was 127.7 mL/min/1.73 m2, and GFR in subject 15 was 62.2 mL/min/1.73 m2. Concentrations and time were
plotted on a 2-phase exponential decay curve, using Graphpad Prism®, version 5.0d (Graphpad software, Inc.). The black line connects the Iohexol
concentrations, the red line depicts the steady state concentration.
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the method is applied to acutely unwell patients, who
will be unstable with changing parameters of GFR and
Vd. However, the CILDI method is simple to apply and
will enable the measurement of both plasma and renal
clearance of Iohexol in critically ill patients, thus provid-
ing a measure of dynamic changes in GFR and allowing
the direct investigation in vivo of the impact of physio-
logical and pathological perturbations on renal function
for the first time.Conclusion
We have developed a tool for measuring GFR in stable
populations that is now ready to be tested in patients at
risk of AKI. In our trial, all subjects achieved a steady-
state concentration within 10 h. Measurements made
after this time in critically ill patients that change by
more than 10.3% likely represent changing GFR and de-
pict evolving AKI. The next stage is to investigate the
applicability of CILDI in patients with AKI. We hypothe-
sise that CILDI may be a more sensitive method of de-
tecting and monitoring AKI than changes in SCr and if
proven to be so, may provide a new standard to which
other methods of measuring GFR in AKI are compared.Key messages
 GFR can be accurately and precisely measured by
CILDI.
 GFR that varies by >10.3%, using CILDI, represents
AKI (p < 0.003).
 Time to steady state in subjects with GFR >28 mL/
min/1.73 m2 is <10 hours in all subjects.
 CILDI is now ready to be investigated in patients
with AKI and at risk of AKI.
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